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Abstract
Background: The emergence of  drug-resistant strains of  Mycobacterium tuberculosis has become a global public health problem. 
Polyherbal medicines offer great hope for developing alternative drugs for the treatment of  tuberculosis.
Objective: To evaluate the anti-tubercular activity of  polyherbal medicines used for the treatment of  tuberculosis.
Methods: The remedies were screened against Mycobacterium tuberculosis H37Rv using Middlebrook 7H9 media and MGIT BAC-
TEC 960 system. They were liquid preparations from King Williams Town site A (KWTa), King Williams Town site B (KWTb), 
King Williams Town site C (KWTc), Hogsback first site (HBfs), Hogsback second site (HBss), Hogsback third site (HBts), East 
London (EL), Alice (AL) and Fort Beaufort (FB).
Results: The susceptibility testing revealed that all the remedies contain anti-tubercular activity with KWTa, KWTb, KWTc, 
HBfs, HBts, AL and FB exhibiting more activity at a concentration below 25 µl/ml. Furthermore, MIC values exhibited in-
hibitory activity with the most active remedies from KWTa, HBfs and HBts at 1.562 µg/ml. However, isoniazid showed more 
inhibitory activity against M. tuberculosis at 0.05 µg/ml when compare to the polyherbal remedies.
Conclusion: This study has indicated that these remedies could be potential sources of  new anti-mycobacterial agents against 
M. tuberculosis. However, the activity of  these preparations and their active principles still require in vivo study in order to assess 
their future as new anti-tuberculosis agents.
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Introduction
Mycobacterium tuberculosis, the leading causative agent of  
tuberculosis (TB) is responsible for the morbidity and 
mortality of  a large population worldwide1. TB has a long 
co-evolutionary history with humans. It does not exhibit 
any symptom of  disease except when impairment of  im-
munity arises due to malnutrition, diabetes, malignancy 
and AIDS2; however, about 10% of  healthy individuals 
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may develop active TB in their life time due to genet-
ic factors. The ability of  TB to resist drugs and the in-
fluence of  HIV epidemic has made the disease remain 
a devastating global public health problem3. According 
to WHO4, one-third of  the world’s population have been 
infected with Mycobacterium tuberculosis (MTB). In 2014, an 
estimated number of  9.6 million new TB infections were 
reported, of  which 5.4 million were men; 3.2 million were 
women and 1.0 million children3. This disease is responsi-
ble for approximately two million deaths annually5.
Some of  the main obstacles to the global control of  the 
disease are the HIV epidemic that has dramatically in-
creased the risk of  developing active TB, increasing emer-
gence of  multidrug resistant-TB (MDR-TB: resistance to 
isoniazid and  rifampin) and refractory nature of  latent 
TB treatment to conventional anti-TB drugs6,7,8,9. The sit-
uation is further exacerbated by the increasing develop-
ment of  extensively drug-resistant (resistant to MDR-TB, 
all fluoroquinolones and at least one of  the second-line 
anti-TB injectable drugs including amikacin, kanamycin 
and/or capreomycin)10,11. According to the modes of  
action of  these drugs, they can be grouped as cell wall 
inhibitors (isoniazid, ethambutol, ethionamide, cycloser-
ine), nucleic acid synthesis inhibitors (rifampicin and 
quinolones), protein synthesis inhibitors (streptomycin, 
kanamycin) and inhibitors of  membrane energy metab-
olism (pyrazinamide)12,13,14. For instance, Isoniazid (INH 
)is the most widely used treatment for TB and its latent 
infections15. This drug enters the cell as a pro-drug, which 
is activated by MTB catalase-peroxidase enzyme (KatG). 
The enzyme activates INH and facilitates its interaction 
with various toxic reactive species (oxides, hydroxyl rad-
icals and organic moieties) in the bacterial cell16, thereby, 
weakening the components of  the cell wall and finally, 
the death of  the bacteria17. INH targets inhA enzyme 
(enoylacyl carrier protein reductase), which is involved in 
the elongation of  fatty acids in mycolic acid synthesis18. 
The replacement of  an amino acid in the NADH binding 
site of  inhA results into INH resistance, preventing the 
inhibition of  mycolic acid biosynthesis19. INH-resistant 
strains often lose catalase and peroxidase activities due to 
KatG Ser315Thr mutation20. Resistance to INH can also 
occur through mutations in the promoter region of  inhA, 
leading to over expression of  inhA, or by mutations at the 
inhA active site, thereby lowering inhA affinity for INH21.
Rifampicin (RIF) have been used as first-line drug in com-
bination with other therapies for the treatment of  TB in-
fections. RIF is believed to inhibit bacterial DNA-depen-
dent RNA polymerase9. This drug interferes with RNA 
synthesis by binding to the β subunit of  mycobacterial RNA 
polymerase, which is encoded by rpoB, thereby killing 
the organism. Resistance to RIF arises due to missense 
mutations in the gene. Mtb resistance to RIF occurs at 
a frequency of  10−7 to 10−8 as a result of  mutations 
in rpoB22. About 96% of  all mutations are found in the 
81-bp core region of  the gene between codons 507 and 
533, with the most common changes occurring in codons 
Ser531Leu,His526Tyr and Asp516Val23.
  
Pyrazinamide (PZA) is another vital first-line drug used 
for the treatment of  TB. It plays an important role in re-
ducing the duration of  TB treatment24. PZA is a pro-drug 
that requires conversion to its active form, pyrazinoic acid 
(POA) by the mycobacterial enzyme pyrazinamidase/nico-
tinamidase. The efflux system of  the mycobacterial cell 
enables massive accumulation of  POA in the bacterial cy-
toplasm, leading to disruption of  the bacterial membrane 
potential25,26. The exact mechanism of  PZA resistance 
remains unknown9. However, PZA resistance has been 
associated with defective pyrazinamidase/nicotinamidase 
activity which results from mutations that might occur at 
different regions (3-17, 61-85 and 132-142) of  pyrazin-
amidase/ nicotinamidase27.
Ethambutol (EMB) is a first-line drug used in combina-
tion with INH, RIF and PZA preventing the emergence 
of  drug resistance mycobacterium. This drug interferes with 
the cell wall of  MTB through a synthetic mechanism 
thereby inhibiting arabinosyl-transferase (embB), an en-
zyme involved in cell wall biosynthesis28. The enzyme 
has been proposed as the target of  EMB in Mtb11. Mu-
tation is the cause of  EMB resistance and it occurs at a 
rate of  approximately 1 in 107 organisms. It increases the 
production of  arabinosyl-transferase, which overwhelms 
the inhibitory effects of  EMB. Studies have revealed five 
mutations in codon 306 accounting 70–90% of  all EMB 
resistant strains29. The resistance of  Mtb to TB-drugs 
is mostly due to mutation which is a cause for concern. 
Therefore, it is important to search for new anti-tuberculo-
sis agents, preferably those that can be readily and simply 
produced from medicinal plants.
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It has been estimated that about 80% of  South African 
population is infected with tuberculosis, with 88% high-
est prevalence of  latent TB among the age group of  30-
39 years old living in the rural settlements30. However, 
the strains of  drug resistant tuberculosis have been on 
increase yearly in the country31.
Polyherbal remedies have been used extensively for the 
treatment of  various diseases for many centuries. They 
are mixtures of  various herbs which contain multiple 
active constituents and act synergistically against infec-
tions32. Natural products and/or their semi-synthetic 
derivatives are important sources of  new chemical com-
pounds that might play an important role in the chemo-
therapy of  tuberculosis33. Several studies on the use of  
polyherbal medicines have revealed that these therapies 
possess pharmacological functions. For instance, Rajanya-
malakadi, a polyherbal preparation which contains three 
herbal ingredients has been proven to show significant 
anti-diabetic, hypolipidemic and anti-oxidant properties34. 
Also, Polyherbal health tonic tea used for the treatment 
of  an array of  diseases affecting humans and Sanjivani 
Vati used for the treatment of  cough and cold have been 
shown to possess significant pharmacological activi-
ties35,36. Other Polyherbal remedies such as Livina, Rhuma-
par tablet, Diakyur and Sugar Remedy have been proven 
to contain pharmacological activities37,38,39,40.
Many researchers have reported on the inhibitory prop-
erties of  medicinal plants against Mycobacterium tuberculosis 
both in South Africa and in other countries33,41,42 but there 
is a dearth of  information on the inhibitory properties 
of  polyherbal medicines against this organism. The aim 
of  the present study therefore was to evaluate polyherbal 
remedies used for the treatment of  TB for anti-Mycobacte-
rium tuberculosis activities.
  
Materials and methods
Collection of  polyherbal medicines
A total of  nine polyherbal medicines evaluated in this 
study were purchased from herbal sellers in five com-
munities namely; Alice, Fort Beaufort, Hogsback, King 
Williams Town and East London in Amathole District 
Municipality of  the Eastern Cape Province, South Africa 
(Figure 1). Each remedy was labelled and coded according 
to the place of  collection; viz: King Williams Town site A 
(KWTa), King Williams Town site B (KWTb), King Wil-
liams Town site C (KWTc), Hogsback first site (HBfs), 
Hogsback second site (HBss), Hogsback third site (HBts), 
East London (EL), Alice (AL) and Fort Beaufort (FB). 
The small number of  remedies obtained in this study was 
due to the fact that only a few traditional healers treat 
and sell remedies for TB. They claim to have acquired 
the knowledge from their ancestors; and this knowledge 
is been transferred from one generation to another.  The 
herbal ingredients present in each of  the remedies are 
shown in Table 1. The remedies were already prepared 
with water by the herbal sellers into clean 2-litre contain-
ers. They were then transported to Medicinal Plants and 
Economic Development Research Centre, University of  
Fort Hare for analysis.
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 Figure 1: Map of Amathole District Municipality43 
Table 1: Herbal ingredients present in each of the polyherbal medicines used for the 
treatment of tuberculosis in Amathole district municipality, 
Eastern Cape Province, South Africa 
 
 Source: Famewo et al. (44) 
  
Name/code Local name Botanical name Parts 
used 
AL Mountain garlic 
Mlomo mnandi 
Red carrot 
Inongwe 
Mnonono 
River pumpkin 
Herbal menthol leaf 
Herbal buchu water 
Allium sativum (L.) 
Glycyrrhiza glabra (L.) 
Daucus carota (L.) 
Hypoxis argentea (Fiscand) 
Strychnos  decussata (Pappe) Gilg 
Gunnera perpensa (L.) 
Mentha piperita (L.) 
Agathosma betulina (Berg) 
Rhizome 
Root 
Root 
corms 
Bark 
Rhizome  
Leaf 
Leaf 
EL Inongwe 
Intelezi 
Ngcambumvuthuza 
Inqwebeba 
Iqwili 
Hypoxis argentea (Fiscand) 
Haworthia reinwardtii (Haw) 
Ranunculus multifidus (Forssk) 
Albuca flaccid (Jacq.) 
Alepidea amatymbica (Eckl. & Zeyh.) 
corms 
Leaf 
Root 
Leaf 
Rhizome 
FB Buchu leaf 
Mountain garlic 
Ginger 
Chilli pepper 
Agathosma betulina (Berg) 
Allium sativum (L.) 
Zingiber officinalis (L.) 
Capsicum annuum (L.) 
Leaf 
Rhizome 
Rhizome 
Fruit 
KWTa Maphipha 
Mnonono 
Ixonya 
Inongwe 
Sicimamlilo 
Iphuzi 
Rapanea melanophloeos (L.) 
Strychnos decussate (Pappe) Gilg 
Kniphofia drepanophylla (Baker) 
Hypoxis argentea (Fiscand) 
Pentanisia prunelloides (Klotzsch) 
Centella eriantha (Rich.) 
Bark 
Bark 
Root 
Corms    
Rhizome  
Rhizome 
KWTb Umdlavuza 
Mnonono 
Inceba emhlophe 
Lauridiatetragonia (L.F.) Strychnos 
decussate (Pappe) Gilg 
Hermannia sp. (L.) 
Root 
Bark 
Root 
KWTc Mnonono Strychnos decussate (Pappe) Gilg Bark 
HBfs Red carrot 
Mlungu mabele 
Calmoes 
Mountain garlic 
Daucus carota (L.) 
Zanthoxylum capense (Thunb.) 
Acorus calamus (L.) 
Allium sativum (L.) 
Root 
Bark 
Rhizome 
Rhizome 
HBss Buchu leaf 
Chilli pepper 
Agathosma betulina (Berg) 
Capsicum annuum (L.) 
Leaf 
Vegetable 
HBts Maphipha 
Red carrot 
Uroselina 
Mountain garlic 
Rapanea melanophloeos (L) Mez 
Daucus carota (L.) 
Cinnamomum camphora (L.) J. Presl 
Allium sativum (L.) 
Bark 
Root crop 
Bark 
Rhizome 
Name/code Local name Botanical name Parts used
AL Mountain garlic
Mlomo mnandi
Red carrot
Inongwe
Mnonono
River pumpkin
Herbal menthol leaf
Herbal buchu water
Allium sativum (L.)
Glycyrrhiza glabra (L.)
Daucus carota (L.)
Hypoxis argentea (Fiscand)
Strychnos decussata (Pappe) Gilg
Gunnera perpens (L.)
Mentha piperita (L.)
Agathosma betulina (Berg)
Rhizome
Root
Root
corms
Bark
Rhizome
Leaf
Leaf
EL Inongwe
Intelezi
Ngcambumvuthuza
Inqwebeba
Iqwili
Hypoxis argentea (Fiscand)
Haworthia reinw rdtii (Haw)
Ranunculus multifidus (Forssk)
Albuca flaccid (Jacq.)
Alepidea amatymbica (Eckl. & Zeyh.)
corms
Leaf
Root
Leaf
Rhizome
FB Buchu leaf
Mountain garlic
Ginger
Chilli pepper
Agathosma betulina (Berg)
Allium sativum (L.)
Zingiber officinalis (L.)
Capsicum annuum (L.)
Leaf
Rhizome
Rhizome
Fruit
KWTa Maphipha
Mnonono
Ixonya
Inongwe
Sicimamlilo
Iphuzi
Rapanea melanophloeos (L.)
Strychnos decussate (Pappe) Gilg
Kniphofia drepanophylla (Baker)
Hypoxis arge tea (Fiscand)
Pentanisi pr nelloides (Klotzsch)
Centella eriantha (Rich.)
Bark
Bark
Root
Corms
Rhizome
Rhizome
KWTb Umdlavuza
Mnonono
Inceba emhlophe
Lauridiatetragonia (L.F.)
Strychnos decussate (Pappe) Gilg
Hermannia sp. (L.)
Root
Bark
Root
Name/code Local name Botanical name Parts used
KWTc Mnonono Strychnos decussate (Pappe) Gilg Bark
HBfs Red carrot
Mlungu mabele
Calmoes
Mountain garlic
Daucus carota (L.)
Zanthoxylum capense (Thunb.)
Acorus calamus (L.)
Allium sativum ( .)
Root
Bark
Rhizome
Rhizome
HBss Buchu leaf
Chilli pepper
Agathosma betulina (Berg)
Capsicum annuum (L.)
Leaf
Vegetable
HBts Maphipha
Red carrot
Uroselina
Mountain garlic
Rapanea melanophloeos (L) Mez
Daucus carota (L.)
Cinnamomum camphora (L.) J. Presl
Allium sativum (L.)
Bark
Root crop
Bark
Rhizome
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Sample preparation
The already prepared water remedies were put in 2-li-
ter containers. Each remedy was filtered with a Buchner 
funnel and Whatman No. 1 filter paper. The filtrate ob-
tained was frozen at -40°C and freeze dried for 48h using 
a freeze dryer (Vir–Tis benchtop K, Vir–Tis Co., Gar-
diner, NY). The resulting sample was dissolved in 100% 
dimethylsulfoxide (DMSO) to a concentration of  50 mg/
ml to make a stock solution45.
Microbial strain and medium used for the assays
Reference MTB strain H37Rv (ATCC 25618) was used 
for the anti-Mycobacterium tuberculosis assay. It was obtained 
from American Type, MD, USA Culture Collection. Bac-
terial culture with DMSO (1.2%), isoniazid (INH) at 
MIC99 (0.05 µg/ml) and bacterial culture only were used 
as controls46.
Bacterial culture and drug preparation
Suspensions of  Mycobacterium tuberculosis H37Rv were 
grown using mycobacterial growth indicator tubes (MGIT). 
The inocula were prepared from Lowenstein–Jensen 
slants. To prepare an inoculum that was less than 15 days 
old from a culture grown on Lowenstein-Jensen medium, 
a suspension was prepared in saline and adjusted to a 1.0 
McFarland standard. The suspension was vortexed for 
several minutes and was allowed to stand for 20 min for 
the initial settling of  larger particles. The supernatant was 
transferred to an empty sterile tube and was allowed to 
stand for an additional 15 min. After being transferred to 
a new sterile tube, it was then adjusted to a 0.5 McFarland 
turbidity standard by visual comparison. A 1:5 dilution 
of  the bacterial suspension was prepared, and 0.5 ml was 
inoculated into MGIT 7H12® (MGIT 960 system, Bec-
ton Dickinson, Sparks, USA) tubes containing test and 
control compounds46.
The growth of  the organism was monitored through 
fluorescent changes due to oxygen consumption in the 
medium during active growth. Aliquots (100 µl) of  each 
herbal medicine was added to the MGIT tubes contain-
ing bacteria in Middlebrook 7H12® media, with the fi-
nal DMSO concentration not exceeding 1.2%. The tubes 
were incubated at 37°C in MGIT system, and growth 
units (GU) were monitored for six days. All the remedies 
were tested at concentrations of  50 and 25 ug/ml46.
For MIC99 evaluations, a 1% bacterial control culture 
was prepared in a drug-free MGIT tube and the MIC99 of  
the compound determined relative to the growth units of  
the control (GU–400). The MIC was determined as the 
lowest drug concentration that equals or lower than GU 
of  the 1% bacterial culture. Controls that were also in-
cluded are bacterial culture with DMSO (1.2%), isoniazid 
(INH) and bacterial culture only. All the herbal prepara-
tions were tested at two-fold decreasing concentration46.
Results
In the present study, the susceptibility and minimum in-
hibitory concentration (MIC) of  nine polyherbal medi-
cines were determined against M. tuberculosis H37Rv, in 
vitro. The susceptibility testing revealed that all the rem-
edies have anti-tubercular activity against M. tuberculosis 
H37Rv at concentrations below 50 ug/ml. Seven of  these 
polyherbal preparations, namely; KWTa, KWTb, KWTc, 
HBfs, HBts, AL and FB showed activity at concentra-
tions below 25 ug/ml, with the remaining remedies show-
ing activity at concentrations between 25 and 50 ug/ml 
(Table 2).
All the remedies exhibited inhibitory activity against M. 
tuberculosis H37Rv with KWTa, HBfs and HBts as the 
most active remedies at 1.562 µg/ml, followed by AL 
remedy which showed growth inhibition at 3.125 µg/ml. 
The remaining preparations from KWTb, KWTc, HBss, 
EL and FB showed growth inhibition against M. tubercu-
losis at 25 µg/ml. However, isoniazid showed more inhib-
itory activity against M. tuberculosis H37Rv at 0.05 µg/ml 
when compared to the polyherbal remedies (Table 2).
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Table 2. Susceptibility testing and minimum inhibition concentration (MIC99) of nine 
polyherbal remedies against M. tuberculosis H37Rv using MGIT BACTEC 960 system 
Polyherbal 
remedies 
Susceptibility 
activity  (µg/ml) 
MIC99 of the remedies 
(µg/ml) 
KWTa < 25 < 1.562 
KWTb < 25 25 
KWTc < 25 25 
HBfs < 25 < 1.562 
HBss > 25 25 
HBts < 25 < 1.562 
AL < 25 3.125 
EL > 25 25 
FB < 25 25 
Isoniazid (INH) - 0.05 
  
Discussion
Tuberculosis has been a major health problem for devel-
oping countries including South Africa. The increasing 
resistance of  the disease to first and second line drugs has 
demanded the need for a new search for anti-mycobacteri-
al agents that could be effective, efficient, non-toxic and 
cost effective47.
The herbal preparations from KWTa, HBfs, HBts and 
AL showed a greater anti-mycobacterial activity, resulting in 
lower susceptibility patterns and MIC values observed. 
From observation, the aforementioned remedies contain 
a mixture of  two or more of  the following herbs: Allium 
sativum, Strychnos decussata, Daucus carota, Hypoxis argentea, 
Rapanea melanophloeo together with other herbs. Species of  
these plants have been investigated and shown to contain 
anthraquinones, glycosides, saponins, tannins, terpenoids, 
aloin, saponins, steroids and flavonoids48,49,50. Other 
compounds include alkaloids, terpenes, resin, monoter-
penoids, sesquiterpenoids and phenols which show activ-
ity against Mycobacterium tuberculosis51,15,52. Allium sativum is 
a plant that has been reported as an established remedy 
for the treatment of  tuberculosis53. It possesses variety 
of  biological properties such as anti-cancer, anti-micro-
bial, antioxidant, immunomodulatory, anti-inflammatory, 
hypoglycaemic and anti-cardiovascular properties54. Sev-
eral studies conducted on the in vitro activity of  Allium 
sativum against Mycobacterium tuberculosis revealed that this 
plant possesses anti-tubercular properties41,42,53,53. The 
presence of  sulphur compounds such as allicin, ajoene, 
allylmethyltrisulfide, diallyltrisulfide, diallyldisulphide has 
been associated with the anti-tubercular activity of  this 
Allium sativum55.
Information on the use of  Strychnos decussate as an anti-tu-
bercular agent has not been reported. This study is the 
first to report the use of  this plant as a remedy for the 
treatment of  TB. However, it has been reported to pos-
sess anti-fungal activity56. Daucus carota is a root vegetable. 
There are only a few reports on the anti-tubercular activ-
ity of  this plant57,58. However, it has been reported to be 
used as an anti-bacterial59, anti-fertility60, anti-oxidant61, 
ophthalmic and stimulant62, anti-septic, diuretic, hepato-
protective, anti-inflammatory63,64, anti-helmintic, carmi-
native65, deobstruent, diuretic and galactogogue. Accord-
ing to the reports, phenolics, polyacetylenes, carotenoids, 
ascorbic acid and tocopherol are the most abundant phy-
tonutrients present in this plant66. Hypoxis argentea has also 
been reported to be used as a remedy for the treatment 
of  TB58. Species of  the genus Hypoxis have been used as 
anti-bacterial, anti-fungal, anti-viral, anti-oxidant, anti-in-
flammatory, anti-diabetic, cardiovascular, anti-convulsant 
and anti-cancer67,68,69,70,71. The presence of  several com-
pounds, especially glucosides, sterols and sterolins could 
be responsible for the different activities found in Hy-
poxis72. Rapanea melanophloeo has been screened for activity 
and found active against drug-resistant and drug-sensitive 
strains of  Mycobacterium tuberculosis73,74. This plant has been 
reported to contain bioactive compounds such as ben-
zoquinones, saponins and tannins which could probably 
contribute to its activity73.
The high activity of  these polyherbal remedies against M. 
tuberculosis could be attributed to the presence of  multiple 
active constituents which may act in synergy and produce 
greater anti-mycobacterial activity. This is an indication that 
many natural products are potential source of  antimyco-
bacterial agents42.
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Conclusion
This study has revealed that polyherbal remedies have the 
potential to cure tuberculosis. This is the first research 
work on the anti-tuberculosis activity of  polyherbal medi-
cines used for the treatment of  tuberculosis in South Af-
rica. The remedies might be potential sources of  new an-
ti-mycobacterial agents as they all showed activity against 
M. tuberculosis. However, the activity of  these remedies 
and their active principles still require in vivo study in or-
der to validate their potential as anti-tuberculosis agents.
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